Recombinant NY-ESO-1 cancer antigen: Production and purification under cGMP conditions

R. Murphy; S. Green; G. Ritter; L. Cohen; D. Ryan; W. Woods; M. Rubira; J. Cebon; I. D. Davis; A. Sjolander; A. Kypridis; H. Kalnins; M. McNamara; M. B. Moloney; J. Ackland; G. Cartwright; J. Rood; G. Dumsday; K. Healey; D. Maher; E. Maraskovsky; Y. T. Chen; E. W. Hoffman; L. J. Old; A. M. Scott

doi:10.1081/PB-200054732

Recombinant NY-ESO-1 cancer antigen: Production and purification under cGMP conditions

R. Murphy, S. Green, G. Ritter, L. Cohen, D. Ryan, W. Woods, M. Rubira, J. Cebon, I. D. Davis, A. Sjolander, A. Kypridis, H. Kalnins, M. McNamara, M. B. Moloney, J. Ackland, G. Cartwright, J. Rood, G. Dumsday, K. Healey, D. MaherE. Maraskovsky, Y. T. Chen, E. W. Hoffman, L. J. Old, A. M. Scott

Research output: Contribution to journal › Article › Research › peer-review

38 Citations (Scopus)

Abstract

The cancer-testis antigen, NY-ESO-1, has been engineered into a bacterial expression plasmid which incorporates a His₆-tag. The plasmid was transfected into E. coli strain BL21 and Master and Working cell banks generated from this expression system. Three 15-litre fermentations were performed under cGMP (code of Good Manufacturing Practice) conditions and the crude NY-ESO-1 tagged protein isolated as solubilised inclusion bodies. A three-step cGMP chromatography process (immobilised metal affinity, anion exchange, and hydrophobic interaction) was utilised to purify the protein. The purified NY-ESO-1 is being used in early stage human cancer vaccine trials in Australia and the U.S.A.

Original language	English
Pages (from-to)	119-134
Number of pages	16
Journal	Preparative Biochemistry & Biotechnology
Volume	35
Issue number	2
DOIs	https://doi.org/10.1081/PB-200054732
Publication status	Published - 10 May 2005

Keywords

Cancer-testis antigen
cGMP
NY-ESO-1
Recombinant protein

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1081/PB-200054732

Cite this

Murphy, R., Green, S., Ritter, G., Cohen, L., Ryan, D., Woods, W., Rubira, M., Cebon, J., Davis, I. D., Sjolander, A., Kypridis, A., Kalnins, H., McNamara, M., Moloney, M. B., Ackland, J., Cartwright, G., Rood, J., Dumsday, G., Healey, K., ... Scott, A. M. (2005). Recombinant NY-ESO-1 cancer antigen: Production and purification under cGMP conditions. Preparative Biochemistry & Biotechnology, 35(2), 119-134. https://doi.org/10.1081/PB-200054732

@article{e0176549838b499f893cc23ddc5f097e,

title = "Recombinant NY-ESO-1 cancer antigen: Production and purification under cGMP conditions",

abstract = "The cancer-testis antigen, NY-ESO-1, has been engineered into a bacterial expression plasmid which incorporates a His6-tag. The plasmid was transfected into E. coli strain BL21 and Master and Working cell banks generated from this expression system. Three 15-litre fermentations were performed under cGMP (code of Good Manufacturing Practice) conditions and the crude NY-ESO-1 tagged protein isolated as solubilised inclusion bodies. A three-step cGMP chromatography process (immobilised metal affinity, anion exchange, and hydrophobic interaction) was utilised to purify the protein. The purified NY-ESO-1 is being used in early stage human cancer vaccine trials in Australia and the U.S.A.",

keywords = "Cancer-testis antigen, cGMP, NY-ESO-1, Recombinant protein",

author = "R. Murphy and S. Green and G. Ritter and L. Cohen and D. Ryan and W. Woods and M. Rubira and J. Cebon and Davis, \{I. D.\} and A. Sjolander and A. Kypridis and H. Kalnins and M. McNamara and Moloney, \{M. B.\} and J. Ackland and G. Cartwright and J. Rood and G. Dumsday and K. Healey and D. Maher and E. Maraskovsky and Chen, \{Y. T.\} and Hoffman, \{E. W.\} and Old, \{L. J.\} and Scott, \{A. M.\}",

year = "2005",

month = may,

day = "10",

doi = "10.1081/PB-200054732",

language = "English",

volume = "35",

pages = "119--134",

journal = "Preparative Biochemistry \& Biotechnology",

issn = "1082-6068",

publisher = "Taylor \& Francis",

number = "2",

}

Murphy, R, Green, S, Ritter, G, Cohen, L, Ryan, D, Woods, W, Rubira, M, Cebon, J, Davis, ID, Sjolander, A, Kypridis, A, Kalnins, H, McNamara, M, Moloney, MB, Ackland, J, Cartwright, G, Rood, J, Dumsday, G, Healey, K, Maher, D, Maraskovsky, E, Chen, YT, Hoffman, EW, Old, LJ & Scott, AM 2005, 'Recombinant NY-ESO-1 cancer antigen: Production and purification under cGMP conditions', Preparative Biochemistry & Biotechnology, vol. 35, no. 2, pp. 119-134. https://doi.org/10.1081/PB-200054732

TY - JOUR

T1 - Recombinant NY-ESO-1 cancer antigen

T2 - Production and purification under cGMP conditions

AU - Murphy, R.

AU - Green, S.

AU - Ritter, G.

AU - Cohen, L.

AU - Ryan, D.

AU - Woods, W.

AU - Rubira, M.

AU - Cebon, J.

AU - Davis, I. D.

AU - Sjolander, A.

AU - Kypridis, A.

AU - Kalnins, H.

AU - McNamara, M.

AU - Moloney, M. B.

AU - Ackland, J.

AU - Cartwright, G.

AU - Rood, J.

AU - Dumsday, G.

AU - Healey, K.

AU - Maher, D.

AU - Maraskovsky, E.

AU - Chen, Y. T.

AU - Hoffman, E. W.

AU - Old, L. J.

AU - Scott, A. M.

PY - 2005/5/10

Y1 - 2005/5/10

N2 - The cancer-testis antigen, NY-ESO-1, has been engineered into a bacterial expression plasmid which incorporates a His6-tag. The plasmid was transfected into E. coli strain BL21 and Master and Working cell banks generated from this expression system. Three 15-litre fermentations were performed under cGMP (code of Good Manufacturing Practice) conditions and the crude NY-ESO-1 tagged protein isolated as solubilised inclusion bodies. A three-step cGMP chromatography process (immobilised metal affinity, anion exchange, and hydrophobic interaction) was utilised to purify the protein. The purified NY-ESO-1 is being used in early stage human cancer vaccine trials in Australia and the U.S.A.

AB - The cancer-testis antigen, NY-ESO-1, has been engineered into a bacterial expression plasmid which incorporates a His6-tag. The plasmid was transfected into E. coli strain BL21 and Master and Working cell banks generated from this expression system. Three 15-litre fermentations were performed under cGMP (code of Good Manufacturing Practice) conditions and the crude NY-ESO-1 tagged protein isolated as solubilised inclusion bodies. A three-step cGMP chromatography process (immobilised metal affinity, anion exchange, and hydrophobic interaction) was utilised to purify the protein. The purified NY-ESO-1 is being used in early stage human cancer vaccine trials in Australia and the U.S.A.

KW - Cancer-testis antigen

KW - cGMP

KW - NY-ESO-1

KW - Recombinant protein

UR - http://www.scopus.com/inward/record.url?scp=20244384857&partnerID=8YFLogxK

U2 - 10.1081/PB-200054732

DO - 10.1081/PB-200054732

M3 - Article

C2 - 15881594

AN - SCOPUS:20244384857

SN - 1082-6068

VL - 35

SP - 119

EP - 134

JO - Preparative Biochemistry & Biotechnology

JF - Preparative Biochemistry & Biotechnology

IS - 2

ER -

Recombinant NY-ESO-1 cancer antigen: Production and purification under cGMP conditions

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Cite this